Closing the door on pharma? A national survey of family medicine residencies regarding industry interactions

Academic Medicine

Volumn 86, Issue 5, 2011, Pages 649-654

  Fugh Berman, Adriane ^a,b   Brown, Steven R ^c   Trippett, Rachel ^d   Bell, Alicia M ^a   Clark, Paige ^e   Fleg, Anthony ^e   Siwek, Jay ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b PharmedOut   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e American Medical Student Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959972713     PISSN: 10402446     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACM.0b013e318212e8d4     Document Type: Article

References (38)

1. Sierles FS, Brodkey AC, Cleary LM, et al. Medical students' exposure to and attitudes about drug company interactions: A national survey. JAMA. 2005;294:1034-1042. (Pubitemid 41248444)
2. Huang FY, Weiss DS, Fenimore PG, et al. The association of pharmaceutical company promotional spending with resident physician prescribing behavior. Acad Psychiatry. 2005;29:500-501.
3. Tsang J, Rudychev I. The sample equation. Med Mark Media. 2006;41:53-58.
4. Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? A randomized controlled trial. Am J Med. 2005; 118:881-884. (Pubitemid 41097466)
5. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000;15:478-483. (Pubitemid 30640259)
6. Brewer D. The effect of drug sampling policies on residents prescribing. Fam Med. 1998;30:482-486. (Pubitemid 28331138)
7. Roughead EE, Harvey KJ, Gilbert AL. Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Aust N Z J Med. 1998;28:306-310. (Pubitemid 28322354)
8. Morelli D, Koenigsberg MR. Sample medication dispensing in a residency practice. J Fam Pract. 1992;34:42-48.
9. Spiller LD, Wymer WW. Physicians' perceptions and uses of commercial drug information sources: An examination of pharmaceutical marketing to physicians. Health Mark Q. 2001;19:91-106.
10. Shaughnessy AF, Slawson DC, Bennett JH. Drug samples. J Fam Pract. 1993;37:533.
11. Strang D, Gagnon M, Molloy W, et al. National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives. Ann R Coll Physicians Surg Can. 1996;29:474-478.
12. Banks JW, Mainous AG. Attitudes of medical school faculty toward gifts from the pharmaceutical industry. Acad Med. 1992 67 610-612 http://journals.lww. com/academicmedicine/Abstract/1992/09000/Attitudes-of-medical-school-faculty- toward-gifts.17.aspx. Accessed January 28 2011.
13. Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing patterns. Fam Med. 2002;34:729-731. (Pubitemid 35340407)
14. Groves KEM, Sketris I, Tett SE. Prescription drug samples-Does this marketing strategy counteract policies for quality use of medicines? J Clin Pharm Ther. 2003;28:259-271.
15. Accreditation Council for Graduate Medical Education. Principles to Guide the Relationship Between Graduate Medical Education and Industry.http://www. acgme.org/acWebsite/positionPapers/pp-GMEGuide.pdf. Accessed January 14, 2011.
16. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. JAMA. 2006;295:429-433. (Pubitemid 43144979)
17. Association of American Medical Colleges. Industry Funding of Medical Education: Report of an AAMC Task Force. http://services.aamc.org/publications/ showfile.cfm?file-version114.pdf&prd-id-232. Accessed January 14, 2011.
18. Institute of Medicine of the National Academies. Conflict of Interest in Medical Research, Education, and Practice. http://www.iom.edu/Reports/2009/ Conflict-of-Interest-in-Medical-research-Educationand-Practice.aspx. Accessed January 14, 2011.
19. Josiah Macy Jr. Foundation. Continuing Education in the Health Professions: Improving Healthcare Through Lifelong Learning. http://www.macyfoundation.org/publications/publication/conferenceproceedings- continuing-education-in-thehealth-professions. Accessed July 1, 2010.
20. Loertscher LL, Halvorsen AJ, Beasley BW, Holmboe ES, Kolars JC, McDonald FS. Pharmaceutical industry support and residency education: A survey of internal medicine program directors. Arch Intern Med. 2010;170:356-362.
21. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training: A thematic review. J Gen Intern Med. 2005;20:777-786. (Pubitemid 41141015)
22. Nakayama DK, Bozeman AP. Industry support of graduate medical education in surgery. Am Surg. 2009;75:395-400.
23. Wang Y, Adelman RA. A study of interactions between pharmaceutical representatives and ophthalmology trainees. Am J Ophthalmol. 2009;148:619-622.
24. Brotzman GL, Mark DH. Policies regulating the activities of pharmaceutical representatives in residency programs. J Fam Pract. 1992;34:54-57.
25. American Academy of Family Physicians. Family medicine residency programs by structure, 2008-2009. http://www.aafp.org/online/en/home/aboutus/specialty/ facts/22.html. Accessed January 14, 2011.
26. Crabtree BF, Miller WL, eds. Doing Qualitative Research. 2nd ed. Thousand Oaks, Calif: SAGE Publications; 1999.
27. Pharmaceutical Research and Manufacturers of America. Code on Interactions With Healthcare Professionals, 2008. http://www.phrma.org/about/ principles-guidelines/codeinteractions-healthcare-professionals. Accessed February 28, 2011.
28. Montague BT, Fortin AH, Rosenbaum J. A systematic review of curricula on relationships between residents and the pharmaceutical industry. Med Educ. 2008;42: 301-308. (Pubitemid 351230177)
29. Lexchin J. What information do physicians receive from pharmaceutical representatives? Can Fam Physician. 1997;43:941-945. (Pubitemid 127776791)
30. Sernyak M, Rosenheck R. Experience of VA psychiatrists with pharmaceutical detailing of antipsychotic medications. Psychiatr Serv. 2007;58:1292-1296. (Pubitemid 350043579)
31. Shaughnessy AF, Slawson DC, Bennett JH. Teaching information mastery: Evaluating information provided by pharmaceutical representatives. Fam Med. 1995;27:581-585.
32. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110:551-557.
33. Segovis CM, Mueller PS, Rethlefsen ML, et al. If you feed them, they will come: A prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center. BMC Med Educ. 2007;7:22-27.
34. Brotzman GL, Mark DH. The effect of resident attitudes of regulatory policies regarding pharmaceutical representative activities. J Gen Intern Med. 1993;8:130-134. (Pubitemid 23101934)
35. McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA. 2001;286:1994-1999. (Pubitemid 33010218)
36. Ferguson RP, Rhim E, Belizaire W, Egede L, Carter K, Lansdale T. Encounters with pharmaceutical sales representatives among practicing internists. Am J Med. 1999;107: 149-152. (Pubitemid 29383969)
37. Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med. 2007;356:1742-1750. (Pubitemid 46658706)
38. Rothman DJ, Chimonas S. New developments in managing physician-industry relationships. JAMA. 2008;300:1067-1073.